1. Introduction {#sec1}
===============

α-Calcitonin gene-related peptide (CGRP) is a 37-amino-acid neuropeptide that is well-known for exerting vasodilation and for controlling lipid and carbohydrate metabolism in adipose tissue, liver, and muscle [@bib1], [@bib2], [@bib3]. CGRP is widely distributed in the central and peripheral nervous systems, including sensory and motor neurons [@bib3]. Motor neurons release CGRP at the neuromuscular junction (NMJ) of skeletal muscle, where it binds to CGRP receptors to induce both short and long-term actions mainly through cyclic adenosine monophosphate (cAMP)/protein kinase A (PKA)/cAMP response element binding protein (CREB) signaling pathway [@bib3], [@bib4], [@bib5], [@bib6].

NMJs are specialized chemical synapses between motor neurons and skeletal muscle fibers, and they mediate muscle contractions. Dysfunction of NMJs leads to a variety of neuromuscular disorders, including congenital myasthenic syndromes (CMS) and myasthenia gravis (MG) [@bib7], [@bib8], [@bib9]. Loss of nerve-muscle communication caused by degeneration of motor neurons or motor neuron denervation (DEN) leads to increased turnover of nicotinic acetylcholine receptors (AChR) and muscle proteolysis [@bib10], [@bib11], [@bib12], [@bib13], [@bib14]. Recently, it has been demonstrated that CGRP exerts trophic effects on the postsynaptic apparatus components in myotubes and mature muscles [@bib15], [@bib16], [@bib17]. For example, application of CGRP increased the number and activity of AChR at the plasma membrane of primary myotubes *in vitro* [@bib16], [@bib18]. Conversely, disruption of CGRP signaling accelerated the degeneration of NMJ and the loss of muscle performance induced by DEN [@bib19]. However, the precise mechanisms by which CGRP maintains the metabolic stability of the AChR at NMJ as well as its regulatory effects on muscle protein metabolism under basal and muscle atrophy conditions have remained elusive.

Under catabolic conditions, the involvement of autophagy and calpains on the degradation of AChR and muscle proteolysis was found [@bib13], [@bib20], [@bib21]. Autophagy is involved in the degradation of cytoplasmic targets, organelles, and plasma membrane proteins in a lysosome-dependent manner [@bib21], [@bib22], [@bib23], [@bib24]. The activation of this system requires the induction of forkhead box O3 (FoxO3) transcription factor, which plays a critical role in muscle atrophy and is necessary and sufficient for the induction of autophagy in skeletal muscle *in vivo* and *in vitro* [@bib11]. FoxO3 controls the transcription of autophagy-related genes, including microtubule-associated protein 1 light chain 3 beta (*Map1lc3b*), gamma-aminobutyric acid (GABA) A receptor-associated protein-like 1 (*Gabarapl1*), and cathepsin L (*Ctsl*) [@bib11], [@bib25]. In addition, muscle protein breakdown and autophagy may also be regulated by the mechanistic target of rapamycin complex 1 (mTORC1) pathway [@bib26], [@bib27]. Although previous studies have shown that mTORC1 is required for regulation of NMJ homeostasis in Drosophila [@bib28], in mammals such role on the NMJ remains unknown. Besides autophagy, also calpains play an important function on muscle protein metabolism and NMJ homeostasis [@bib12], [@bib13], [@bib29], [@bib30]. Calpains are activated upon atrophic conditions, including muscle DEN [@bib10], [@bib31], [@bib32] and in myasthenic models [@bib12]. Furthermore, they may play a key role in the early steps of disassembly of sarcomeric proteins [@bib29], impairment of neuromuscular transmission [@bib12], and dispersion of AChR clusters at NMJ (Chen et al., 2007). The activation of the calpain system requires the elevation of intracellular Ca^2+^ levels [@bib29] and consequent activation of calpain-1 and -2, the most abundant isoforms of the family of Ca^2+^-dependent cysteine proteases. Upon DEN the elevation of cytosolic Ca^2+^ levels [@bib33], [@bib34], NMJ degeneration [@bib15], [@bib20] and muscle atrophy [@bib10], [@bib11], [@bib34] are observed. Dispersion of AChR clusters at NMJs [@bib12], [@bib13] and muscle protein degradation induced by calpains are inhibited by overexpression of its endogenous inhibitor calpastatin [@bib12], [@bib13] as well as by cAMP agonists [@bib35].

Although both the autophagic/lysosomal and the calpain systems are upregulated in several models of muscle atrophy [@bib11], [@bib29], [@bib36], their regulation by extracellular signals is controversial and not fully understood. We and others [@bib10], [@bib30], [@bib35], [@bib37] have demonstrated that cAMP-inducing agents, including catecholamines, beta-2 adrenergic agonists, and cAMP-phosphodiesterase inhibitors, inhibit these proteolytic processes. Similarly, also CGRP is capable of inducing cAMP production in muscle [@bib38]. CGRP exerts a direct inhibitory action on autophagic-lysosomal proteolysis in extensor digitorum longus muscles (EDL) of denervated rats [@bib38]. This suggests that CGRP might exert beneficial effects on NMJs upon DEN through its inhibitory action on autophagy and calpain systems, thus preserving the amount of AChR in the synapse of atrophic skeletal muscle. Here, we found that treatment with CGRP *in vivo* rescued the reduction of NMJ area in skeletal muscle of denervated mice, an effect that is apparently mediated through mTORC1 and the suppression of autophagy. In addition, the present data show that the Ca^2+^-dependent proteolytic system is also inhibited by CGRP, a mechanism that could also be important for the maintenance of the synapse.

2. Materials and methods {#sec2}
========================

2.1. Animals, treatments and DEN surgery {#sec2.1}
----------------------------------------

For the majority *in vivo* experiments, sham-operated and 7-days-denervated, 12-wk-old C57/BL6 male mice, treated or not with CGRP (100 μg kg^−1^; C0292 -- Sigma--Aldrich) were used. Four-wk-old male Wistar rats, sham-operated and 7-days-denervated, treated or not with CGRP were also used for some *in vivo* experiments, in which the protein levels of the components from the Ca^2+^-dependent proteolysis were measured. For *in vitro* experiments, isolated muscles incubated in the presence or absence of CGRP (10^−6^ M) from sham-operated and 7-days-denervated, 4-wk-old male Wistar rats were used. Subsequently, rates of proteolysis, proteolytic activities, protein synthesis, expression of mRNA and protein levels of the components from the Ca^2+^-dependent proteolysis system, phosphorylation of the proteins from PKA/CREB signaling pathway, and intracellular levels of cAMP were measured in these samples. Young rats were used for *in vitro* experiments, because this procedure requires intact and sufficiently thin muscles to allow adequate diffusion of metabolites and oxygen [@bib39]. Denervation was performed by dissecting out about 2 mm of the sciatic nerve roughly 1 cm above the popliteal fossa while the animals were under anesthesia (10 mg kg^−1^ ketamine and 85 mg kg^−1^ xylazine). DEN was chosen as an atrophy model because it induces a significant loss of contractile proteins and AChR degradation [@bib10], [@bib23]. All animals were housed in a room with a 12-h light, 12-h dark cycle and were given free access to water and a normal laboratory chow diet. All experiments and protocols were in accordance with the ethical principles for animal experimentation adopted by the Brazilian College of Animal Experimentation and approved by Ribeirão Preto Medical School of the University of São Paulo-The Ethics Committee on Animal Use (CEUA 184/2010).

2.2. Evaluation of protein metabolism in rat isolated muscles {#sec2.2}
-------------------------------------------------------------

After euthanasia, isolated muscles used for determining *in vitro* protein synthesis or proteolysis were rapidly weighed, maintained at its resting length by holding their tendons in aluminum supports, and incubated at 37 °C in Krebs--Ringer bicarbonate buffer (pH 7.4, 5 mM glucose, equilibrated with 95% O~2~ and 5% CO~2~). Innervated and denervated muscles were incubated with either saline or CGRP. The concentration of CGRP for *in vitro* experiments was based on a dose--response curve of anti-proteolytic action of this peptide using rat isolated muscles [@bib38].

2.3. Measurements of *in vitro* protein synthesis {#sec2.3}
-------------------------------------------------

*Soleus* muscles from normal and DEN rats were incubated in a Krebs--Ringer bicarbonate buffer that contained all amino acids at concentrations similar to those of rat plasma [@bib40]. After a 1 h equilibration period, L-\[U-^14^C\]tyrosine (0.05 μCi/ml) was added to the replacement medium and muscles were incubated for another 2 h. The rate of tyrosine incorporated into proteins using the specific activiy of the intracellular pool of tyrosine of each muscle was calculated.

2.4. Measurements of *in vitro* overall proteolysis and proteolytic activities {#sec2.4}
------------------------------------------------------------------------------

After 2 h of incubation of rat *soleus* muscles in Krebs--Ringer bicarbonate buffer, the overall proteolysis and Ca^2+^-dependent proteolytic activity were determined by measuring the rate of tyrosine release in the incubation medium in the presence of cycloheximide (0.5 mM). Ca^2+^-dependent proteolysis was measured as described previosly [@bib10]. Tyrosine release was assayed using a fluorometric method [@bib41].

2.5. Nonradioactive measurements of *in vivo* and *in vitro* protein synthesis with SUnSET {#sec2.5}
------------------------------------------------------------------------------------------

For *in vivo* measurements of protein synthesis, mice were treated with an intraperitoneal injection of 0.040 μmol g^−1^ puromycin (P8833 -- Sigma--Aldrich) dissolved in 100 μl of PBS. 30 min after injection, *gastrocnemius* muscles were extracted for western blot analysis (IV-SUnSET) of puromycin-labeled peptides. For *in vitro* measurements of protein synthesis, C2C12 myotubes were incubated for 30 min with media containing puromycin (1 μM). After 30 min of incubation with puromycin, the cells were extracted for the analysis of the amount of puromycin-labeled peptides by western blot.

2.6. *In vivo* electroporation of cDNA in mice skeletal muscle {#sec2.6}
--------------------------------------------------------------

Skeletal muscles were transfected by an optimized electroporation protocol based on the use of spatula electrodes to transfer cDNA *in vivo* into *tibialis anterior* (TA) muscle. peYFP-hLC3 (YFP-LC3) was kindly provided by Dr. M. Sandri (Venetian Institute of Molecular Medicine, Padua, Italy), pEGFP-N1 was obtained from Addgene Vector Database. Mice were anesthetized and a minor incision was performed on the hindlimb to expose the TA. This was injected with 30 μl of 0.9% saline containing 15 μg of purified plasmid DNA. Electric pulses were then applied using an electric pulse generator (CUY21; Tokiwa Science, Fukuoka, Japan) and two stainless steel spatula electrodes placed on each side of the isolated muscle. Four square-wave pulses with a pulse length of 20 ms and 200 ms intervals between each pulse were delivered at 21 V followed by four other pulses with the opposite polarity.

2.7. *In vivo* visualization of AChR puncta at NMJ and *in vivo* and *ex vivo* NMJ immunofluorescence {#sec2.7}
-----------------------------------------------------------------------------------------------------

### 2.7.1. In vivo visualization of AChR puncta at NMJ {#sec2.7.1}

BGT-AlexaFluor647 (25 pmol, Life Technologies, B35450) was injected 24 h prior to microscopy into the TA to label surface exposed receptors, some of which are subsequently endocytosed. For *in vivo* visualization of AChR and NMJ area, green fluorescent BGT-AlexaFluor488 (25 pmol, Life Technologies, B13422) was injected 24 h prior to microscopy into the TA. The superficial 200 μm of TA were examined *in vivo* with an upright Leica SP2 (Leica Microsystems) confocal microscope equipped with a 63 ×/1.2 NA water immersion objective. 3D stacks at 512 × 512-pixel resolution were taken [@bib21]. Images were electronically processed using ImageJ/Fiji software (NIH). For quantitative analysis of vesicle numbers, the following procedure was used. The channel containing positive signals to BGT-AlexaFluor488 at NMJ was counted. This procedure yielded total amounts of AChR puncta per NMJ [@bib21].

### 2.7.2. Whole muscles NMJ staining {#sec2.7.2}

Mouse *soleus* or TA muscles were rinsed in PBS and then fixed in 4% paraformaldehyde for 30 min [@bib42]. Subsequently, the samples were rinsed for 3 × 10 min in PBS/glycine 0.1 M for 30 min and rinsed 3 × 10 min in PBS again. Then, the samples were quenched in ice cold 100% methanol for 5 min at −20 °C, rinsed for 3 × 10 min in PBS, and bathed in fluorescently conjugated BGT (diluted 1 : 200 in PBS) for 30 min. The muscles were mounted on slides with Dako fluorescent mounting medium and glass coverslips, sealed by clear nail polish on two sides. All imaging was performed on a Carl Zeiss LSM 7 MP Multiphoton Microscope using a 40 × objective. Maximum intensity projections of optical sections were created with ImageJ/Fiji software. The NMJ area labeled with BTX-488 was quantified using ImageJ, normalized for each experimental condition to the control.

2.8. Quantitative PCR {#sec2.8}
---------------------

Total RNA was prepared from mouse TA muscles and C2C12 cells using TRIzol (Invitrogen^®^, Carlsbad, CA) kit. Complementary DNA was generated with Advantage ImProm-II reverse transcriptase (Promega^®^, Madison, WI). Real-time PCR was carried out using an ABI7500 sequence detection system (Applied Biosystems^®^, Foster City, CA). A SuperScript III Platinum SYBR Green One-Step RT-qPCR Kit with ROX (Invitrogen^®^) was used. The primers used are described in [Table 1](#tbl1){ref-type="table"}.Table 1PCR primer sequences.Table 1ForwardReverseRat *Capn2*5′ GAAGCCTCCCAATTTGTT 3′5′ CAGTGACGGAGTACGCATGTC 3′Rat *Cast*5′GCRATCACAGGACCTCTTCCAGA 3′5′GGTGAAATCAGATGACAAGGCA3′Mouse *Capn2*5′GTTCTCTGCTTGGCTGCTCTA 3′5′ CCTGATGCGGATCAATTTCTG 3′Mouse *Cast*5′ATAGCTGCCCCTCAACTACAGA 3′5′TCTTTAGCCTTTGGCTTGGACA 3′Mouse *Map1lc3b*5′ CGTCCTGGACAAGACCAAGT 3′5′ ATTGCTGTCCCGAATGTCTC 3′Mouse *Gabarapl1*5′CATCGTGGAGAAGGCTCCTA3′5′ ATACAGCTGGCCCATGGTAG 3′Mouse *ctsl*5′GTGGACTGTTCTCACGCTTCAAG 3′5′ TCCGTCCTTCGCTTCATAGG 3′Mouse *Becn1*5′GGCCAATAAGATGGGTCTGA 3′5′CACTGCCTCCAGTGTCTTCA 3′Mouse *Rpl39*5′ CAAAARCGCCCTATTCCTCA 3′5′ AGACCCAGCTTCGTTCTCCT 3′Rat *Rpl39*5′ TCCTGGCAAAGAAACAAAAGC 3′5′ TAGACCCAGCTTCGTTCTCCT 3′Mouse *Chrng*5′ CCAGAATGGCTCTTCCTCAG 3′5′ GCTCTGCACTTCTGG 3′Mouse *Chrne*5′GAGGGAGGCTATGTGAGCTG 3′5′ACGGCAAAGATGAACTCCAC 3′Mouse *Chrna1*5′TGCGGAAGGTTTTTATCGAC 3′5′ CGGAGAGTGAAAGCCCATAG3′Mouse *atrogin-1*5′TGAACATCATGCAGAGGCTGA3′5′GATCAAACGCTTGCGAATCTG3′Mouse *Murf1*5′ACCTGCTGGTGGAAAACATC 3′5′ACCTGCTGGTGGAAAACATC 3′Mouse *Tfeb*5′CCACCCCAGCCATCAACAC3′5′CAGACAGATACTCCCGAACCTT3′

2.9. Western blot analysis {#sec2.9}
--------------------------

Muscle tissues (mouse *gastrocnemius* and rat *soleus*) and C2C12 cells were lysed and immunoblotted with anti-LC3 (1 : 1000; Cell Signaling 2775S); anti-calpain 1 large subunit detecting full-length calpain 1 as well as calpain 1 autoproteolytically cleaved at leucine 28 residue (1 : 750; Cell Signaling \#2556S); anti-calpastatin (1 : 750; Cell Signaling \#4146S); anti-phospho S6-(Ser235/236) (1 : 1000; Cell Signaling \#2211S); anti-phospho-Ser256 FoxO1 (1 : 750; Cell Signaling \#9461); phospho-Thr32 FoxO3 and phospho-Thr24 FoxO1 (1 : 750; Cell Signaling \#9464); FoxO1 (1 : 1000; Cell Signaling \#9454); FoxO3 (1 : 1,000; Sigma--Aldrich AV38041); phospho-Thr37/46 4EBP1 (1 : 1,000; Cell Signaling \#2855); 4EBP1 (1 : 1000; Cell Signaling \#9452); phospho-Ser240/244 S6 (1 : 1000; Cell Signaling \#2215); S6 (1 : 1000; Cell Signaling \# \#2217); anti-α-actinin (1 : 1000; Sigma--Aldrich A7811); anti-p35 (1 : 750; Santa Cruz Biotechnology sc-820); anti-Cdk5 (1 : 500; Santa Cruz Biotechnology sc-173); anti-endophilin-B1 (1 : 500; Santa Cruz Biotechnology sc-134843); anti-α-tubulin (1 : 1000; Santa Cruz Biotechnology sc-32293); anti-β-actin (1 : 1000; Santa Cruz Biotechnology sc-81178). Primary antibodies were detected using peroxidase-conjugated secondary antibodies (1 : 5000 for β-actin or α-tubulin and 1 : 1000 for the other primary antibodies) and visualized using ECL reagents by an ImageQuant 350 detection system (GE Healthcare, Piscataway, NJ). Band intensities were quantified using ImageJ (version 1.43u, National Institutes of Health, USA).

2.10. Determination of plasma insulin and muscle cAMP levels {#sec2.10}
------------------------------------------------------------

Serum insulin levels and muscular cAMP levels were measured using a method based on a competitive enzyme immunoassay system (Millipore -- EZRMI-13 k and GE Healthcare -- RPN225, respectively).

### 2.10.1. Immunofluorescence on C2C12 myotubes and hela cells {#sec2.10.1}

To investigate the expression of AChR and the colocalization of calpain-1 with AChR, C2C12 myotubes cultured on poly-[l]{.smallcaps}-lysine (Sigma--Aldrich)-coated coverslips were fixed in 4% paraformaldehyde for 10--15 min. To study autophagic flux, HeLa cells (ATCC), were grown on coverslips and maintained in GM until 80--90% of confluency. Subsequently, the cells were transfected with YFP-LC3 vector using Lipofectamine™ 3000 (Thermo Fisher Scientific, Inc., Waltham, MA) according to the manufacturer\'s instructions. After 48 h of transfection, autophagy was induced by 2 h of incubation in starvation condition using Hank\'s Balanced Salt Solution (HBSS -- GIBCO®). Because autophagy is a dynamic process with autophagosome synthesis, autophagosome fusion with the lysosome, and lysosomal degradation of autophagic substrates, the autophagic flux was analyzed in the presence of either, autophagolysosomal fusion inhibitors (chloroquine, 50 μM; C6628 -- Sigma--Aldrich; or bafilomycin A1, 100 nM; B1793 -- Sigma--Aldrich), an mTOR inhibitor (rapamycin, 300 nM; R8781 -- Sigma--Aldrich), or of CGRP. Then, cells were washed three times with PBS, permeabilised with 0.5% v/v Triton X-100 in PBS for 10 min and blocked with 5% w/v bovine serum albumin (BSA) in PBS for 45 min at room temperature. Coverslips were again washed three times with PBS and incubated overnight at 4 °C with anti-calpain 1 antibody (Santa Cruz Biotechnology; N-19; goat polyclonal; 1 : 100) in PBS containing 2% w/v BSA. Subsequently, cells were washed three times and followed by an incubation for 1 h with anti-goat IgG (1 : 200; Alexa Fluor 488-conjugated), DAPI (1 : 1000), and BGT-Alexa 647 (BTX-647; 1 : 200; Thermo Fisher Scientific). The fluorescence intensities of BGT, calpain-1 immunofluorescence, and YFP-LC3 puncta were assessed by confocal microscopy (Carl Zeiss LSM 7 MP Multiphoton Microscope using a 63× objective). BGT-488 or BGT-647 were quantified using ImageJ/Fiji as the intensity of the fluorescence signal minus background cytoplasmic fluorescence, normalized for each experimental condition to the control. Signals of AlexaFluor488-conjugated anti-goat IgG which stained calpain 1 was quantified using ImageJ/Fiji through automatic counting of the numbers of particles, normalized for each experimental condition to the control. The fluorecescence intensity of BGT-Alexa Fluor 488/647 was quantified using ImageJ/Fiji, normalized for each experimental condition to the control.

### 2.10.2. Luciferase reporter assay {#sec2.10.2}

C2C12 cells were grown on in GM until 80--90% of confluency. Subsequently, cells were transfected with DBE-FoxO or MuRF1 luciferase and pRL-null-Renilla luciferase using Lipofectamine™ 3000 (Thermofisher) according to the manufacturer\'s protocol. DBE-FoxO, MuRF1 Luciferase, and pRL-null-Renilla luciferase were kindly provided by Dr. M. Sandri (Venetian Institute of Molecular Medicine, Padua, Italy). Thereafter, GM medium was replaced with differentiation medium and experiments were performed after 3 days. C2C12 cells were homogenized in Passive Lysis Buffer using Tissue Lyzer (Qiagen), and luciferase activity was quantified using a Dual-Luciferase Reporter Assay (Promega). Foxo activity was determined by normalizing firefly luciferase activity (DBE-Foxo reporter) to pRL-null-Renilla luciferase activity.

2.11. Statistical analysis {#sec2.11}
--------------------------

Data were displayed as mean ± standard error (SE). The statistical significance of differences was determined by one-way or two-way analysis of variance (ANOVA) followed by multiple comparison tests (Turkey\'s or Bonferroni\'s test). A significance level of 95% (P \< 0.05) was accepted.

3. Results {#sec3}
==========

3.1. CGRP activates cAMP/PKA/CREB signaling pathway and abrogates the reduction of NMJ area {#sec3.1}
-------------------------------------------------------------------------------------------

In agreement with the notion that CGRP exerts its physiological actions mainly through cAMP/PKA/CREB signaling pathway [@bib4], [@bib17], [@bib38], we found that CGRP *in vitro* increased the cAMP levels as well as the phosphorylation levels of several PKA substrates, including CREB in both normal and DEN rat muscles ([Figure 1](#fig1){ref-type="fig"}A--F). cAMP levels increased rapidly within 15 min of CGRP in both control and denervated muscles but remained high until 120 min only in denervated muscles ([Figure 1](#fig1){ref-type="fig"}A,B). It is likely that the higher activity [@bib43] and mRNA levels [@bib44] of adenylyl cyclase accounts for the more-long lasting effect in cAMP levels induced by CGRP in denervated *soleus*. Under *in vivo* conditions, CGRP further increased the DEN-induced phosphorylation levels of PKA substrates and CREB ([Figure 1](#fig1){ref-type="fig"}G,H) in gastrocnemius of mice. Like in muscles, CGRP also activated PKA/CREB signaling in starved C2C12 myotubes ([Figure 1](#fig1){ref-type="fig"}I,J; DMEM low Glucose/Glucose 1 mM and without serum for 24 h). Since CGRP *in vitro* increased the amount of AChR at the plasma membrane [@bib16], we evaluated chronic effects of *in vivo* treatment with CGRP with respect to the maintenance of NMJ area in denervated mice. CGRP treatment for 7 days prevented the reduction (∼30%) of NMJ area in muscles of denervated mice ([Figure 2](#fig2){ref-type="fig"}A,B), but it did not abrogate the DEN-induced loss of muscle mass (Control: 0.523 ± 0.021; DEN: 0.214 ± 0.012; DEN + CGRP: 0.240 ± 0.019 mg.100 g BW^−1^; n = 6--7). As previously described [@bib45], [@bib46], [@bib47], we found that plasma levels of insulin were significantly decreased 1 h after a single injection of CGRP in mice (34.5 ± 8.9 vs 8.02 ± 0.9 μUI/ml in controls). Acute treatment with CGRP at the first and fifth day of DEN partially rescued NMJ degeneration in denervated muscles ([Figure 2](#fig2){ref-type="fig"}C,D). Since CGRP did neither affect the incorporation of puromycin labeled peptides ([Figure 2](#fig2){ref-type="fig"}E,F) nor gene expression of *Chrna1*, *Chrne*, and *Chrng* ([Figure 2](#fig2){ref-type="fig"}G) in denervated rat muscles, the effects on NMJ area were likely not associated with alterations of general muscle protein synthesis or expression of AChR subunits. Also, CGRP did not increase the rates of protein synthesis as estimated by C^14^-tyrosine incorporation into total protein *in vitro* ([Figure 2](#fig2){ref-type="fig"}H). In contrast, CGRP (10^−8^ and 10^−6^ M) reduced the basal rates of tyrosine release by ∼ 25% and attenuated the increase in protein breakdown induced by DEN ([Figure 2](#fig2){ref-type="fig"}I). In agreement with previous studies [@bib48], DEN alone increased protein synthesis as estimated *in vivo* ([Figure 2](#fig2){ref-type="fig"}E,F) and *in vitro* ([Figure 2](#fig2){ref-type="fig"}H). Although the underlying mechanisms are still unknown this effect is likely important for increasing translation of the large number of mRNA species that are transcriptionally up-regulated following muscle inactivity [@bib49]. These results suggest that an antiproteolytic action of CGRP, probably mediated by cAMP/PKA signaling, might be involved in the attenuation of AChR degradation and maintenance of NMJ upon DEN.Figure 1**CGRP activates cAMP/PKA/CREB signaling pathway. (A)** cAMP levels from *soleus* muscles incubated *in vitro* with CGRP (1 μM) from control and (**B**) 7-days denervated rats. (**C**) Western blot and (**D**) densitometric analysis of phosphorylation levels of several substrates of PKA at Ser/Thr sites and CREB at Ser133 site in *soleus* muscles incubated *in vitro* with CGRP for 2 h from control rats. (**E**) Western blot and (**F**) densitometric analysis of phosphorylation levels of several substrates of PKA at Ser/Thr sites and CREB at Ser133 site in *soleus* muscles incubated *in vitro* with CGRP for 2 h from denervated rats. (**G**) Western blot and (**H**) densitometric analysis of phosphorylation levels of several substrates of PKA at Ser/Thr sites and CREB at Ser133 site in *gastrocnemius* muscles from denervated mice treated *in vivo* with a unique bolus of CGRP (100 μg kg^−1^). (**I**) Western blot and (**J**) densitometric analysis of phosphorylation levels of several substrates of PKA at Ser/Thr sites and CREB at Ser133 site in C2C12 myotubes under starvation (24 h of DMEM low glucose and without serum) condition and treated *in vitro* with CGRP for 2 h. Values are expressed as mean ± SEM of 3--5 replicates per group.Figure 1Figure 2**CGRP rescues the reduction of NMJ area in denervated muscles through a mechanism independent of protein synthesis. (A)** AChR in whole *soleus* muscles from 7-days denervated mice daily treated or not with CGRP (100 μg kg^−1^ for 7 days), labeled *ex vivo* with BGT-AlexaFluor488. Subsequently, confocal microscopy was performed and maximum z-projections of NMJs were obtained. (**B)** Quantitative analysis of NMJ area. Graph depicts the average of NMJ area of BGT-AF positive structures. **(C)** AChR in *tibialis* anterior muscles from denervated mice acutely treated or not with two injections of CGRP (100 μg kg^−1^; at first and fifth day), labeled *in vivo* with BGT-AlexaFluor488. Subsequently, confocal microscopy was performed and maximum z-projections of NMJs were obtained. (**D)** Quantitative analysis of NMJ area. Graph depicts the average of NMJ area of BGT-AF positive structures. (**E and F**) *In vivo* effects of one single injection of CGRP (100 μg kg^−1^; 2 h) on protein synthesis estimated by means of puromycin labeled peptides in *gastrocnemius* and on (**G**) mRNA levels of *Chrna1*, *Chrng*, and *Chrne* subunits in *tibialis* anterior muscles of DEN mice. Gene expression was normalized to endogenous control, *Rpl39*, using the ΔΔCT method. (**H**) *In vitro* effects of CGRP (1 μM) on the rates of protein synthesis and on (**I**) overall proteolysis in isolated *soleus* muscles of rats. Data of protein synthesis and overall proteolysis are expressed as % of the values in control muscles considered as 100%, 0.214 ± 0.006 and 0.322 ± 0.010 nmol mg^−1^.2 h^−1^, respectively. Values are expressed as mean ± SEM of 3--5 samples per group.Figure 2

3.2. CGRP inhibits the formation of endo/lysosomal carriers containing AChR and autophagosomes at the NMJ and suppresses autophagy in mouse muscles {#sec3.2}
---------------------------------------------------------------------------------------------------------------------------------------------------

Previous studies have shown that DEN increases endocytic trafficking and degradation of AChR via autophagy in an endophilin-B1- and LC3-dependent manner [@bib20], [@bib21], whilst lysosomal inhibitors decrease AChR degradation in mouse muscle cells [@bib23]. Considering that CGRP inhibits protein degradation *in vitro* ([Figure 2](#fig2){ref-type="fig"}H) and hyperactivity of lysosomal proteolysis in rat denervated muscles [@bib38], we assessed the *in vivo* role of CGRP in the modulation of endo/lysosomal carrier formation containing AChR at the NMJ. Mice were denervated and treated with a single injection of CGRP. After five days, a second injection of CGRP was administered, and after fourteen days the AChR were labeled with BGT-AlexaFluor647. On the following day, i.e. fifteen days after DEN, *in vivo* microscopy was performed. As shown in [Figure 3](#fig3){ref-type="fig"}, CGRP treatment blocked the increase (∼3-fold) of the number of endocytic AChR-positive puncta per NMJ that was observed upon DEN ([Figure 3](#fig3){ref-type="fig"}A,B). In addition, CGRP treatment also blocked the elevation of LC3-positive autophagosomes per NMJ area in denervated muscles ([Figure 3](#fig3){ref-type="fig"}C,D). Previously, it was shown that CDK5 controls the activity of endophilin-B1, and its effects on autophagy in neural and muscles cells [@bib21], [@bib50]. Endophilin-B1 is characterized by a N-BAR domain, necessary for phospholipid bilayer binding and curvature induction as well as a C-terminal SH3 domain, that allows interaction with proline-rich proteins, such as UVRAG (UV radiation resistance associated gene) protein [@bib51]. In particular, binding of endophilin-B1 to UVRAG protein mediates Beclin1 recruitment to the phagophore and autophagy induction [@bib51]. Here, we found that DEN increased the protein content of CDK5, endophilin-B1, and LC3II in mouse skeletal muscle by roughly 2 to 3-fold, an effect that was suppressed by CGRP ([Figure 3](#fig3){ref-type="fig"}E,F). Moreover, *in vivo* treatment with CGRP rescued the ∼3 to 4-fold upregulation of the autophagy-related genes *Beclin-1* (*Becn1*), *Map1lc3b*, *Gabarapl1*, and *Ctsl* in denervated muscles ([Figure 3](#fig3){ref-type="fig"}G). Next, we examined the *in vitro* effects of CGRP on autophagy as induced by starvation in C2C12 cells. This revealed, that CGRP *in vitro* not only decreased the protein levels of LC3II and the ratio of LC3II/LC3I but also suppressed the expression of p62. This suggests that CGRP inhibits the autophagic flux and the autophagy machinery ([Figure 3](#fig3){ref-type="fig"}H,I). To further confirm the effects of CGRP on autophagic flux, we cultured C2C12 myotubes in the presence of HBSS, a serum and nutrient free medium that is well-known to induce autophagy *in vitro* [@bib52]. For the measurement of autophagic flux, myotubes were kept in the absence or presence of Bafilomycin A1, an inhibitor of vacuolar H^+^-ATPase that prevents maturation of autophagic vacuoles by inhibiting fusion between autophagosomes and lysosomes [@bib52]. As expected, the nutritional stress in C2C12 myotubes stimulated the autophagic flux and this effect was blocked by CGRP ([Figure 3](#fig3){ref-type="fig"}J). Consistently, CGRP also suppressed the ∼2 to 6-fold induction of autophagic genes *Becn1*, *Map1lc3b*, and *Gabarapl1* in starved C2C12 myotubes ([Figure 3](#fig3){ref-type="fig"}K). Collectively, these data suggest that CGRP inhibits the endocytosis of AChR at NMJs and the autophagic components involved in AChR degradation upon denervation.Figure 3**CGRP inhibits the endo/lysosomal carriers containing AChR at the NMJ as well as the autophagy in denervated muscles. (A**) AChR in *tibialis* anterior muscles were labeled with BGT-AlexaFluor647 before *in vivo* microscopy analysis of the number of endo/lysosomal carriers containing AChR. Maximum z-projections of NMJs from control and DEN mice acutely treated with CGRP (100 μg kg^−1^). Arrowheads indicate BGT-AF positive endo/lysosomal carriers. (**B)** Quantitative analysis of endo/lysosomal carriers. Graph depicts the average amount of BGT-positive vesicles per NMJ. (**C)** AChR in whole *tibialis* anterior muscles from 7-days denervated mice electroporated with YFP-LC3, daily treated or not with CGRP (100 μg kg^−1^ for 7 days) was labeled *ex vivo* with BGT-AlexaFluor647. Subsequently, the confocal microscopy was performed and the maximum z-projections of NMJs were obtained and YFP-LC3^+^ puncta were automatically counted using Fiji software. (**D**) Numbers of YFP-LC3^+^ puncta per NMJ area. (**E**) Western blot and (**F**) densitometric analysis of Cdk5, endophilin-B1 and LC3 protein content normalized to α-actinin from *gastrocnemius* muscles of DEN mice treated with a single injection of CGRP. (**G)** RT-qPCR analysis of *Becn1*, *Map1lc3b*, *Gabarapl1*, and *Ctsl* from *tibialis* anterior muscles of DEN mice treated with a single injection of CGRP. Gene expression was normalized to endogenous control, *Rpl39*, using the ΔΔCT method. (**H**) Western blot and (**I**) densitometric analysis of LC3 and p62 protein levels in C2C12 myotubes under starvation (24 h of DMEM low glucose and without serum) condition and treated *in vitro* with CGRP for 2 h. (**J**) Western blot analysis of LC3 in C2C12 myotubes incubated *in vitro* in starvation (HBSS for 6 h) condition with CGRP (1 μM) in the presence of bafilomycin A1 (100 nM). (**K)** RT-qPCR analysis of *Becn1*, *Map1lc3b*, *Gabarapl1*, and *Ctsl* from C2C12 myotubes incubated *in vitro* in HBSS for 3 h with CGRP. Gene expression was normalized to endogenous control, *Rpl39*, using the ΔΔCT method. In the quantitative analysis, values are expressed as mean ± SEM of 3--5 replicates per group.Figure 3

3.3. CGRP inhibits the induction of FoxO family members and TFEB in mouse cell muscles {#sec3.3}
--------------------------------------------------------------------------------------

Because previous studies found that FoxO controls the expression of autophagy-related genes [@bib11], [@bib53], [@bib54], we investigated the role of CGRP on the expression and activity of FoxO family members in mouse skeletal muscles upon atrophic conditions. In denervated mouse muscles, acute treatment with CGRP increased the phosphorylation levels of FoxO3a and FoxO1 ([Figure 4](#fig4){ref-type="fig"}A,B). Besides FoxO, the transcription factor EB (TFEB) is a newly discovered transcriptional factor and considered to act as a master regulator of autophagy and lysosomal biogenesis [@bib55]. Here, we observed a DEN-induced elevation of *Tfeb* gene expression that was suppressed by *in vivo* treatment with CGRP ([Figure 4](#fig4){ref-type="fig"}C). Since the E3-ubiquitin ligase *MuRF1* is involved in the degradation of AChR at the NMJ [@bib24] of atrophic muscles in an autophagy-dependent mechanism [@bib20] and its expression is modulated by FoxO [@bib54] and TFEB [@bib56], we next tested the effects of CGRP on gene expression of MuRF1. Interestingly, the elevation of *MuRF1* induced by DEN was abrogated by *in vivo* treatment with CGRP ([Figure 4](#fig4){ref-type="fig"}D). Fittingly, CGRP *in vitro* increased the phosphorylation levels of several FoxO family members ([Figure 4](#fig4){ref-type="fig"}E,F) and blocked the upregulation of FoxO transcriptional activity ([Figure 4](#fig4){ref-type="fig"}G) that were induced by starvation in C2C12 cells. Furthermore, CGRP decreased the gene expression of *Tfeb* ([Figure 4](#fig4){ref-type="fig"}H) and *Murf1* ([Figure 4](#fig4){ref-type="fig"}I) as well as MuRF1 transcriptional activity ([Figure 4](#fig4){ref-type="fig"}J) under these conditions. Taken together, these data suggest that the transcriptional inhibition of autophagy-related genes and MuRF1 mediated by FoxO and TFEB transcriptional factors are involved in the trophic effect of CGRP on NMJ in denervated muscles.Figure 4**CGRP inhibits the induction of FoxO family members and TFEB in mouse cell muscles induced by atrophic conditions**. (**A**) Western blot and (**B**) densitometric analysis of FoxO1-(Ser256) and FoxO3-(Thr32) phosphorylation levels normalized to β-actin from *gastrocnemius* muscles of 7-days denervated mice treated with a single injection of CGRP (100 μg kg^−1^). RT-qPCR analysis of (**C**) Tfeb, (**D**) atrogin1 and MuRF1 from tibialis anterior muscles of DEN mice treated with a single injection of CGRP. Gene expression was normalized to endogenous control, Rpl39, using the ΔΔCT method. (**E**) Western blot and (**F**) densitometric analysis of phosphorylation levels of several FoxO family members in C2C12 myotubes under starvation (24 h of DMEM low glucose and without serum) condition and treated *in vitro* with CGRP for 2 h. (**G**) FoxO transcriptional activity of C2C12 myotubes incubated in HBSS medium in the presence or absence of CGRP (1 μM; 2 h). Firefly/renilla luciferase activity was measured as described in the materials and methods. RT-qPCR analysis of (**H**) Tfeb and (**I**) MuRF1 from C2C12 myotubes incubated *in vitro* in HBSS for 3 h with CGRP. Gene expression was normalized to endogenous control, Rpl39, using the ΔΔCT method. (**J**) MuRF1 transcriptional activity of C2C12 myotubes incubated in HBSS medium in the presence or absence of CGRP (1 μM; 2 h). Firefly/renilla luciferase activity was measured as described in the materials and methods. Values are expressed as mean ± SEM of 3--5 replicates per group. (**I**) MuRF1 from C2C12 myotubes incubated *in vitro* in HBSS for 3 h with CGRP. Gene expression was normalized to endogenous control, Rpl39, using the ΔΔCT method. (**J**) MuRF1 transcriptional activity of C2C12 myotubes incubated in HBSS medium in the presence or absence of CGRP (1 μM; 2 h). Firefly/renilla luciferase activity was measured as described in the materials and methods. Values are expressed as mean ± SEM of 3--5 replicates per group.Figure 4

3.4. mTORC1 mediates the inhibitory effects of CGRP on autophagy and on the maintenance of NMJ in denervated muscles {#sec3.4}
--------------------------------------------------------------------------------------------------------------------

Because mTORC1 inhibits autophagy [@bib26], [@bib55] and is required for the regulation of NMJ homeostasis [@bib28], we investigated whether mTORC1 could mediate the effects of CGRP on NMJ maintenance in denervated muscles. For this purpose, DEN mice were daily treated or not with CGRP for 7 days and/or rapamycin. [Figure 5](#fig5){ref-type="fig"}A,B show that the reduction of the NMJ area induced by DEN was rescued by daily treatment with CGRP, and this effect was blocked by co-treatment with rapamycin. To further demonstrate that CGRP indeed stimulates mTORC1 activity, DEN-mice were acutely treated with a single injection of CGRP and/or rapamycin. In agreement with previous studies [@bib27], DEN alone increased the phosphorylation levels of S6, a downstream target of mTORC1 ([Figure 5](#fig5){ref-type="fig"}C,D). CGRP further enhanced the phosphorylation levels of S6 in denervated muscles and this effect was blocked by rapamycin treatment. In line with the hypothesis that mTORC1 mediates the effects of CGRP on autophagy, we observed that the downregulation on LC3II protein levels induced by the *in vivo* treatment with CGRP was blocked when the mice were cotreated with rapamycin ([Figure 5](#fig5){ref-type="fig"}E,F). In starved C2C12 cells, CGRP increased the phosphorylation levels of S6 (at Ser240 and 244, two specific residues of S6K1) and 4E-BP1 ([Figure 5](#fig5){ref-type="fig"}G,H). We next analyzed the autophagic flux in HeLa cells that were transiently transfected with YFP-LC3 and treated or not with CGRP, chloroquine, and rapamycin. Consistent with our previous observations, the increase in the number of YFP-LC3 puncta upon starvation was blocked by CGRP and this effect, in turn, was reverted by rapamycin ([Figure 5](#fig5){ref-type="fig"}I,J). Taken together, these data suggest that mTORC1 is required for the effects of CGRP on autophagy and the maintenance of NMJ in denervated muscles.Figure 5**The mTORC1 signaling pathway is induced by CGRP and mediates its effects in NMJ area maintenance and autophagy in mice skeletal muscles. (A**) AChR in whole *soleus* muscles from 7-days denervated mice daily treated or not with CGRP (100 μg kg^−1^ for 7 days) and rapamycin (1.5 mg kg^−1^ for 7 days) was labeled *ex vivo* with BGT-AlexaFluor488. Subsequently, the confocal microscopy was performed and the maximum z-projections of NMJs were obtained. (**B)** Quantitative analysis of NMJ area. (**C**) Western blot and (**D**) quantitative analysis of S6-(Ser235/236) phosphorylation levels normalized to β-actin in *gastrocnemius* muscles from denervated mice treated with a single injection of rapamycin (1.5 mg kg^−1^) and/or CGRP (100 μg kg^−1^). (**E**) Western blot and (**F**) quantitative analysis of LC3 protein levels normalized to ɑ-tubulin in *gastrocnemius* muscles from denervated mice treated with a single injection of rapamycin (1.5 mg kg^−1^) and/or CGRP (100 μg kg^−1^). (**G**) Western blot and (**H**) densitometric analysis of phosphorylation levels of S6 at Ser240/244 and 4E-BP1 at Thr37/46 sites in C2C12 myotubes under starvation (24 h of DMEM low glucose and without serum) condition and treated *in vitro* with CGRP for 2 h. (**I**) HeLa cells were transfected with YFP-LC3 and after 48 h the cells were incubated *in vitro* in HBSS medium and treated with chloroquine (50 μM), rapamycin (300 nM), and CGRP (1 μM; 3 h). (**J**) Numbers of YFP-LC3^+^ puncta per Hela cell. Values are expressed as mean ± SEM of 3--5 replicates per group.Figure 5

3.5. CGRP inhibits the Ca^2+^-dependent proteolytic system in denervated skeletal muscles {#sec3.5}
-----------------------------------------------------------------------------------------

Considering that calpains are activated upon denervation [@bib10], [@bib31], [@bib32], impair neuromuscular transmission [@bib12], and are regulated by cAMP/PKA signaling, we evaluated whether CGRP could modulate the activity of the Ca^2+^-dependent proteolytic system in rodent skeletal muscles. As shown in [Figure 6](#fig6){ref-type="fig"}A,B, a single injection of CGRP in denervated mice significantly inhibited the calpain activity as indicated by elevated protein content of autolyzed calpain-1 and p25, the latter being the cleavage form of the calpain substrate protein p35. DEN increased gene expression of *calpain-2* (*Capn2*) and reduced the mRNA levels of *calpastatin (Cast)*, the endogenous inhibitor of calpains, whilst the acute treatment with CGRP abolished such effects ([Figure 6](#fig6){ref-type="fig"}C). Furthermore, in rat muscles *in vitro*, the addition of CGRP to the incubation medium reduced Ca^2+^-dependent proteolysis in both control and denervated muscles by about 20--25% ([Figure 6](#fig6){ref-type="fig"}D). Next, we assessed the role of chronic treatment with CGRP (i.e., for 7 days) in the calpain system in rat muscles. Although chronic treatment with CGRP did not alter calpastatin levels, the protein content of autolyzed calpain-1 was significantly decreased by CGRP ([Figure 6](#fig6){ref-type="fig"}E,F). Taken together, these data show that CGRP directly inhibits the basal and denervation-induced calpain activation in skeletal muscle from rodents.Figure 6**CGRP inhibits the Ca**^**2+**^**-dependent proteolysis and the calpain activity in denervated muscles.** (**A**) Western blot and (**B**) densitometric analysis of p35, p25, and calpain-1 protein content normalized to β-actin from *gastrocnemius* muscles of denervated mice treated with a single injection of CGRP (100 μg kg^−1^; 2 h). (**C**) RT-qPCR analysis of *Capn2* and *Cast* of *tibialis* anterior muscles from denervated mice 2 h after a single injection of CGRP. Gene expression was normalized to endogenous control, *Rpl39*, using the ΔΔCT method. (**D**) *In vitro* effects of CGRP (1 μM) on Ca^2+^-dependent proteolytic activity in control and denervated *soleus* muscles of rats. Data of Ca^2+^-dependent proteolytic activity are expressed as % of the values of the control and denervated muscles considered as 100%, 0.122 ± 0.012 and 0.131 ± 0.007 nmol of Tyr mg^−1^ 2 h^−1^, respectively. (**E**) Western blot and (**F**) densitometric analysis of calpain-1, and calpastatin protein content normalized to α-tubulin in skeletal muscles from control and denervated *soleus* muscles of rats chronically treated with CGRP (100 μg kg^−1^ for 7 days). Values are expressed as mean ± SEM of 3--5 replicates per group.Figure 6

3.6. CGRP suppresses the activation of calpain in muscle cells and in parallel stabilizes AChR at plasma membrane {#sec3.6}
-----------------------------------------------------------------------------------------------------------------

Because cholinergic stimulation causes calpain activation and dispersal of AChR clusters [@bib13], we investigated the *in vitro* effect of CGRP on calpain activity and amount of AChR in muscle cells incubated with carbachol (CCh), a nonhydrolyzable cholinergic agonist. As shown in [Figure 7](#fig7){ref-type="fig"}A, CCh increased the Ca^2+^-dependent proteolysis in isolated rat muscles *in vitro* by about 2.5-fold. This effect was attenuated (∼30%) by CGRP ([Figure 7](#fig7){ref-type="fig"}A). Moreover, CGRP blocked the ∼6-fold increase in autolysis of calpain-1 that was induced by CCh in C2C12 myotubes ([Figure 7](#fig7){ref-type="fig"}B,C). To investigate whether CGRP maintains the stability of AChR at the plasma membrane by a mechanism independent of protein synthesis, C2C12 myotubes were incubated with CCh and/or CGRP in the presence of cycloheximide (CHX), a protein synthesis inhibitor. Subsequently, cells were fixed and AChR were labeled with BGT-AlexaFluor488. As shown in [Figure 7](#fig7){ref-type="fig"}D--G, CGRP treatment rescued the decreased expression of AChR in C2C12 myotubes upon CCh when protein synthesis was inhibited by CHX. As expected, the decreased expression of AChR and the increased number of calpain-1 positive structures ([Figure 7](#fig7){ref-type="fig"}H,I) induced by CCh were both blocked by CGRP in C2C12 myotubes. Importantly, *in vivo* treatment with calpeptin, a well-known cell-permeable calpain inhibitor for 7 days mimicked the effects of CGRP, and partially reverted the reduction of NMJ sizes induced by DEN ([Figure 7](#fig7){ref-type="fig"}J,K). Taken together, these results show that CGRP suppresses the activation of calpain and autophagy in muscle cells and in parallel stabilizes AChR at the plasma membrane.Figure 7**CGRP inhibits the calpains and preserve the amount of AChR at the plasma membrane in muscle cells. (A)***In vitro* effects of CGRP (1 μM) on carbachol (100 μM)-induced activation of Ca^2+^-dependent proteolysis in rat *soleus* muscles. (**B)** Western blot and (**C**) densitometric analysis of the calpain-1 autolysis induced by carbachol (100 μM) and CaCl~2~ (1 mM) in C2C12 myotubes, in the presence or absence of CGRP (1 μM; 3 h). (**D**) Immunofluorescence and (**E**) fluorescence intensity of AChR labeled with BGT-AlexaFluor488 in C2C12 myotubes treated with carbachol (100 μM) and CaCl~2~ (1 mM) in the presence or absence of cycloheximide (500 μM) and/or CGRP (1 μM; 3 h). *In vitro* microscopy was performed, and fluorescence intensity was determined using ImageJ (Fiji). Maximum z-projections of confocal stacks showing automatically segmented of AChR in C2C12 myotubes. The receptors and nucleus signals in the overlay panels are shown in green and blue, respectively. (**F)** Western blot and (**G**) densitometric analysis of AChR in C2C12 myotubes treated with carbachol (100 μM) and CaCl~2~ (1 mM) in the presence or absence of cycloheximide (500 μM) and/or CGRP (1 μM; 3 h). (**H and I**) Immunofluorescence and quantification of AChR and calpain-1 expression in C2C12 myotubes treated with carbachol (100 μM) and CaCl~2~ (1 mM), in the presence or absence of CGRP (1 μM; 3 h). *In vitro* microscopy was performed, and fluorescence intensity was determined using ImageJ (Fiji). Maximum z-projections of confocal stacks showing automatically segmented of AChR in C2C12 myotubes. The AChR labeled with BGT-AlexaFluor647 (far red), calpain labeled with AF488 (green), and nucleus labeled with DAPI (blue) signals in the overlay panels. (**J**) Immunofluorescence and (**K**) average of NMJ area from AChR labeled *ex vivo* with BGT-AlexaFluor488 in whole *soleus* muscles from 7-days denervated mice daily treated or not with calpeptin (15 mg kg^−1^ for 7 days). The results from control and DEN group are the same used in [Figure 5](#fig5){ref-type="fig"}A. Subsequently, the confocal microscopy was performed and the maximum z-projections of NMJs were obtained. Values are expressed as mean ± SEM of 3--5 replicates per group.Figure 7

4. Discussion {#sec4}
=============

The present data show that treatment with CGRP *in vivo* rescued the reduction of NMJ area in skeletal muscle of denervated mice. This effect was associated with suppression of a DEN-induced elevation of the number of endocytic/lysosomal carriers containing AChR at the synapse. Likely, this trophic effect of CGRP at the NMJ was due to reduced AChR degradation, since CGRP *in vitro* increased AChR content in myotubes even in the presence of CHX, a condition that blocks protein synthesis. Moreover, CGRP inhibited overall proteolysis in normal and denervated muscles but did not affect the rate of protein synthesis. Along these lines, it has been consistently shown that lysosomal inhibitors reduce the degradation of AChR in muscle cells demonstrating an important role of this pathway for the regulation of AChR abundance [@bib23]. In a previous study, we have demonstrated that CGRP inhibits lysosomal proteolysis in glycolytic skeletal muscles of rats [@bib38]. In extension to this concept, we now present strong evidence that CGRP suppressed the autophagic flux in denervated oxidative and glycolytic mouse muscles as well as in starved C2C12 myotubes. We found that upon muscle DEN, CGRP treatment blocked the elevation of well-known markers of endocytic/lysosomal carriers involved in the AChR degradation, including Cdk5, endophilin-B1, and LC3II. These data are consistent with the findings that the deletion of Cdk5^−/−^ in primary myotubes increases AChR clusters [@bib57] and that muscle DEN increases the activity of endophilin-B1, a substrate of Cdk5, as well as the degradation of AChR at NMJ through the autophagic-lysosomal system [@bib21]. In fact, the number of vesicles positive for AChR as well as their colocalization with endophilin-B1 were increased upon DEN [@bib21]. Also, we observed that CGRP treatment inhibited the upregulation of *Becn1*, *Map1lc3b*, *Gabarapl1*, and *Ctsl* mRNA levels in either denervated muscles or C2C12 myotubes, indicating that CGRP suppresses the autophagic-lysosomal system, at least in part, by transcriptional mechanisms. Although it cannot be ruled out that these effects might also be due to CGRP-induced changes in mRNA degradation rates of such genes, the present study clearly shows that CGRP inhibits FoxO activity, which is the main transcriptional factor involved in the control of the autophagic-lysosomal system. Previous studies have shown that under atrophic conditions such as muscle DEN or starvation, the transcriptional activity of FoxO is increased and that FoxO activates several autophagy-related genes including *Becn1*, *Map1lc3b*, *Gabarapl1*, and *Ctsl* [@bib11], [@bib53]. In addition, our findings show that CGRP increases the gene expression of TFEB, a transcriptional factor that not only controls the expression of autophagy-related genes [@bib11], [@bib53], but also the expression of genes involved in lysosomal biogenesis [@bib55]. Interestingly, FoxO [@bib54] and TFEB [@bib56] are involved in the control of MuRF1 gene expression, an E3-ligase involved in autophagy-mediated degradation of AChR [@bib20] upon atrophic conditions [@bib24]. In agreement with these findings, we observed that CGRP inhibited DEN-induced upregulation of MuRF1 suggesting that the suppression of this E3-ligase could be an additional mechanism by which CGRP stabilizes AChR at NMJ. Despite these inhibitory effects on MuRF1, CGRP does not modulate the proteolytic activity of the ubiquitin-proteasome system [@bib38]. Since it is well established that loss of innervation causes muscle wasting by the induction of the proteasomal system [@bib58], [@bib59], this could explain why CGRP treatment did not rescue the denervation-induced loss of muscle mass.

Previously, we demonstrated that CGRP exerted its inhibitory actions on FoxO activity through PKA and not AKT [@bib38]. PKA is well known to be involved in the physiological effects of this peptide [@bib3], [@bib4], [@bib17]. Because mTORC1 can be stimulated by both AKT and PKA [@bib60], [@bib61] and negatively controls autophagy [@bib26], [@bib55], we investigated whether mTORC1 might be involved in the suppressive effects of CGRP on autophagy and on NMJ maintenance. Although several studies have shown that mTORC1 exerts an important role on synaptic plasticity in rodent central nervous system [@bib62], [@bib63], [@bib64], [@bib65], [@bib66], to our knowledge there is only one study reporting a role of TORC1 in the maintenance and activity-dependent homeostatic response in NMJ of *Drosophila* [@bib28]. Here, we show that CGRP, like other cAMP-stimulating signals [@bib61], activates mTORC1 signaling in starved C2C12 myotubes and in denervated muscles. Furthermore, rapamycin abolished the effects of CGRP on mTORC1 signaling and autophagy. It is noteworthy that rapamycin also blocked the suppression of autophagosome formation by CGRP as well as the trophic effect of this peptide on the maintenance of NMJ area in denervated muscles. Importantly, mTORC1 is known as the main negative regulator of TFEB activity, autophagy, and lysosomal proteolysis [@bib55], [@bib67], and the lysosome is the main organelle involved in the degradation of AChR [@bib23]. Because CGRP was found to control AChR abundance at the plasma membrane of differentiated myotubes independent of protein synthesis [@bib16], our current and previous data [@bib38] suggest that the ability of CGRP to prevent NMJ degeneration in the setting of DEN is due to the activation of mTORC1, leading to reduced autophagy and AChR degradation. The fact that CGRP activates mTORC1 but does not stimulate protein synthesis is consistent with recent studies, which demonstrated that mTORC1 can inhibit autophagy independent of the control of protein synthesis [@bib68], [@bib69]. Mechanistically, the full activity of mTORC1 depends on its lysosomal localization mediated by the Ragulator-Rag complex [@bib70], [@bib71] followed by its interaction with Rheb [@bib71], a key activator of mTORC1 stimulated by insulin [@bib69]. Therefore, the absence of protein synthesis-inducing effects of CGRP here reported could be explained, at least in part, by the decrease in plasma levels of insulin induced by CGRP treatment *in vivo*. Indeed, CGRP is a well-known inhibitor of insulin secretion [@bib45], [@bib46], [@bib47], an effect that seems to be due to the stimulation of somatostatin release [@bib70].

In agreement with previous studies [@bib10], [@bib13], [@bib29], our data show that the calpain system, as estimated by different approaches including the cleavage of p35 into p25, was activated in denervated skeletal muscles. Fittingly, we have observed that the calpain induction by DEN was completely abolished in skeletal muscle of rats chronically treated with CGRP. Our *in vitro* experiments also showed that CGRP inhibits the increase in the activity of Ca^2+^-dependent proteolysis in isolated muscles and the calpain-1 autolysis in C2C12 myotubes induced by carbachol, a nonhydrolyzable cholinergic agonist that increases the cytosolic Ca^2+^ levels and activates the calpain [@bib13]. Since CGRP also increased the amount of AChR in C2C12 myotubes incubated with carbachol and cycloheximide, CGRP controls AChR levels likely rather via the inhibition of the calpain system than by gene expression mechanisms. That calpain is implicated in the instability of the NMJ is also consistent with the present finding that the *in vivo* treatment with calpeptin, a calpain inhibitor, mimicked the effects of CGRP, and abolished the reduction of NMJ area induced by DEN. Such hypothesis is further supported by the findings that calpain participates in the dispersion and degradation of AChR clusters [@bib13], and that it is activated at NMJs slow-channel myasthenic patients, where Ca^2+^ overload occurs at the NMJ due to mutations in the genes encoding AChR subunits [@bib12]. Interestingly, in a mouse model of this syndrome, transgenic overexpression of calpastatin ameliorated the symptoms and neuromuscular transmission [@bib12], [@bib13].

In summary, the present data suggest that, upon muscle denervation, the trophic effect of CGRP at NMJ is apparently mediated through a cAMP/PKA-dependent pathway, which leads to the transcriptional inhibition of FoxO/TFEB-regulated autophagic genes and stimulation of mTORC1 ([Figure 8](#fig8){ref-type="fig"}). Consequently, the degradation of AChR by autophagy-lysosome system is suppressed in the presence of CGRP. Furthermore, the inhibition of calpain system by CGRP seems to be an additional regulatory mechanism involved in the NMJ stabilization under atrophic conditions. These findings are important for identifying mediators involved in the maintenance of NMJs integrity, which may positively affect muscle function and health.Figure 8**Hypothesis of how CGRP maintains the stability of AChR and suppresses autophagy and calpain systems in denervated skeletal muscle.** 1. CGRP inhibits the transcriptional activity of FoxO and TFEB. FoxO is a well-known transcriptional factor involved in the control of LC3 and autophagy [@bib1]. 2. TFEB is a transcriptional factor master regulator of autophagosome and lysosome biogenesis [@bib2]. 3. Furthermore, mTOR is a direct negative regulator of TFEB activity [@bib2]. 4. Both FoxO3 [@bib3] and TFEB [@bib4] control the gene expression of E3 ubiquitin ligase MuRF1 upon atrophic condition. 5. Downregulation of these two transcriptional factors might explain why CGRP suppresses the induction of many markers of autophagy and lysosome biogenesis upon muscle atrophy condition. 6. It has been shown MuRF1 plays a role in the degradation of AChR at the NMJ under atrophying conditions [@bib5]. 7. Notably, muscle denervation process implied enhanced production of endo/lysosomal carriers of AChR, which also contained the membrane remodeler Bif1, MuRF1, and the selective autophagy receptor 62 [@bib6]. 8. Our data are in agreement these previous studies and suggest CGRP maintains the stability of AChR at the NMJ during muscle denervation through its negative action on LC3, p62, and MuRF1. 9. Previous studies have shown calpains are involved in the degradation of AChR at NMJ [@bib7] under atrophic conditions and PKA inhibits the fragmentation of NMJ induced by atrophic denervation [@bib8]. Since PKA inhibits calpains [@bib9] and because CGRP activates PKA and also inhibits calpain, our data suggest the effects of CGRP in the maintenance of NMJ might depend on the action of this peptide on calpains via PKA. 10. In summary, these results suggest CGRP maintains the stability of AChR at NMJ upon muscle atrophy induced by DEN most likely through its inhibitory action on FoxO and TFEB, a central regulator of autophagosome and lysosome biogenesis and most likely through the inhibitory action of this peptide on calpains.Figure 8
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